On our screens:Cheap stocks by free cash flow yield
Is the price fair?
What SGRY's price assumes
Today's price asks for −2.6% free cash flow growth a year; over the last three years Surgery Partners, Inc. delivered 37%, less than the record.
0.46
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 9.3%
Free cash flow yield · Medical Care Facilities median 7.1%
- Growth the price implies
- −2.6%
Growth the price implies · The price pays for −2.6% free cash flow growth a year for a decade; the business has delivered +37% a year over the last three.
- Price / book
- 0.91
Price / book · as of 2026-Q1
Details›
- Price / book2026-Q1
- 0.91
- Free cash flow, trailing twelve months
- $188M
- Market capitalisation
- $2.02B
- 3-year revenue growth
- +8.2%
- 3-year free cash flow growth
- +37%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.